Actithera Partners with Weizmann Institute for Advanced Radiopharmaceutical Innovations Actithera has secured exclusive rights to pioneering covalent chemistry technologies from the Weizmann Institute to enhance targeted radiopharmaceutical applications for cancer treatment.

Actithera Partners with Weizmann Institute for Advanced Radiopharmaceutical Innovations #United_States #Cambridge #Actithera #Weizmann_Institute #Yeda

Additional Funding Raises: #Nuclidium €84 million Series B; #CarOnSale €70M Series C; #Actithera $75.5M Series A; #Nabla $70M Series C; #ActioBiosciences $66M Series B; #Abacum $60M Series B; #Huspy $59M Series B; #AllayTherapeutics $57.5M Series D; #LookUp €50M Series A

Norway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipeline - ArcticStartup Actithera, an Oslo and Cambridge-based biotech company focused on radioligand therapies, has closed a $75.5 million Series A financing round to support the

#siliconfjord radiopharmaceutical biotech company #Actithera raised $75.5M in Series A funding. @MVenturesTeam, @HadeanV, @SofinnovaVC, and @4biocapital led the round. By @arcticstartup arcticstartup.com/actithera-ra... #NordicMade #nordicbiotech #LifeScience

Actithera Secures $75.5 Million in Oversubscribed Series A to Innovate Radioligand Therapy Actithera has raised $75.5 million in a Series A financing round led by major investors to advance its precision radioligand therapy platform for clinical development.

Actithera Secures $75.5 Million in Oversubscribed Series A to Innovate Radioligand Therapy #Norway #Oslo #Series_A_Financing #Radioligand_Therapy #Actithera